WBWalter Bonfig

Walter Bonfig

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Walter Bonfig has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Genetic characteristics and long-term follow-up of 11 patients with congenital hyperinsulinism followed in a single center

    by Katharina Warncke, Franziska Falco, Wolfgang Rabl, Ilse Engelsberger, Julia Saier, David Flores-Rodriguez, Stefan Burdach, Walter Bonfig

    Background:Congenital hyperinsulinism (CHI) is a rare disease with an estimated incidence of 1:40,000 live births. Here, we characterize 11 patients treated at Munich Children’s Hospital Schwabing.Methods:We analyzed data on birth, treatment and laboratory results including genetic testing and evaluated the long-term course with a follow-up visit.Results:All patients had severe, diazoxide-(DZX)-resistant hypoglycemia, beginning immediately after birth. Two patients were treated by medical therapy, eight underwent subtotal pancreatectomy and one had a partial resection. Both patients who had medical therapy still suffer from occasional hypoglycemia. Six patients with subtotal pancreatectomy were affected by mild hypoglycemia. Seventy-five percent of patients who had surgical treatment developed diabetes mellitus (DM) at a median age of 10.5 (8–13) years. In 89% of patients with available genetic testing, mutations of theConclusions:The majority of CHI-patients not responding to DZX underwent surgery. After subtotal pancreatectomy, patients typically developed diabetes around early puberty.

  • Blood Pressure in a Large Cohort of Children and Adolescents With Classic Adrenal Hyperplasia (CAH) Due to 21-Hydroxylase Deficiency

    by Walter Bonfig, Friedrich-Wilhelm Roehl, Stefan Riedl, Helmut Günther Dörr, Markus Bettendorf, Jürgen Brämswig, Eckhard Schönau, Felix Riepe, Berthold Hauffa, Reinhard W. Holl, et al.

    BACKGROUND Data on blood pressure (BP) in children and adolescents with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency are conflicting in the literature. PATIENTS AND METHODS BP data of n = 716 children and adolescents (aged 3–18 years) from a national CAH database were analyzed. BP data were adjusted for height and compared to contemporary national reference data. A systolic and diastolic BP above the 95th centile was defined as hypertensive. RESULTS Overall prevalence of hypertension was 12.5%. Prevalence of hypertension was higher in younger children than in adolescents (18.5% vs. 4.9%). Until 8 years of age, fludrocortisone dose/m2/day correlated significantly with BP in regression analysis (P < 0.0001). BP correlated significantly with body mass index standard deviation score (BMI-SDS) (P < 0.0001), but not with hydrocortisone dose. In patients with salt-wasting CAH, BMI-SDS and BP were significantly higher compared to patients with simple virilising CAH, P < 0.01. CONCLUSION Especially young CAH children seem to be at risk for—most likely transient—hypertension, since the prevalence of hypertension decreases with age. In children up to 8 years of age, the used fludrocortisone dose is a significant risk factor for hypertension. Therefore we recommend accurate measurement of BP and careful fludrocortisone dosing in children with CAH.


  • Blood pressure, fludrocortisone dose and plasma renin activity in children with classic congenital adrenal hyperplasia due to 21‐hydroxylase deficiency followed from birth to 4 years of age

    by Walter Bonfig, Hans Peter Schwarz

    Summary: Introduction: Infants with congenital adrenal hyperplasia (CAH) require higher doses of fludrocortisone (FC) due to physiological mineralocorticoid resistance. The adequacy of mineralocorticoid replacement should be closely monitored to avoid hypertension.Objective: To evaluate blood pressure (BP) in infants with CAH due to 21‐hydroxylase deficiency.Patients and Methods: Thirty‐three patients (18f/15 m) diagnosed by newborn screening were followed until the age of 4 years. Mean start of HC and FC treatment was day 9·8 ± 9·2 postnatally. Mean daily HC dose ranged from 8·6 to 12·3 mg/m2/day.Results: During the first year of life prevalence of systolic hypertension was up to 45·5%. At 12 and at 18 months, BP was highest. Prevalence of systolic hypertension was up to 57·6% at 18 months of age. After 24 months BP levels were lower and at 48 months prevalence of hypertension decreased to 15·2%. Systolic and diastolic BP correlated significantly with the administered fludrocortisone dose (r = 0·3, P = 0·005), but not with body mass index. Hypertensive children received significantly higher FC doses and had significantly lower plasma renin activity during the study period.Conclusion: High prevalence of transient, most likely FC induced hypertension was found in young children with classic CAH diagnosed by newborn screening. The changing mineralocorticoid sensitivity in infants is a risk factor for the development of hypertension in patients with CAH, who are treated with FC. Therefore suppressed plasma renin activity should be avoided to prevent arterial hypertension.


  • Metabolic Safety of Growth Hormone in Type 1 Diabetes and Idiopathic Growth Hormone Deficiency

    by Walter Bonfig, Katharina Molz, Joachim Woelfle, Sabine E. Hofer, Berthold P. Hauffa, Eckhard Schoenau, Sven Golembowski, Stefan A. Wudy, Reinhard W. Holl


  • A levothyroxine dose recommendation for the treatment of children and adolescents with autoimmune thyroiditis induced hypothyroidism

    by Victoria Ellerbroek, Katharina Warncke, Julia Köhle, Walter Bonfig

    To determine a levothyroxine (T4) dose recommendation for the treatment of autoimmune thyroiditis (AIT)-induced hypothyroidism. T4 doses in 75 children and adolescents with newly diagnosed AIT were prospectively collected and compared to T4 doses of patients with congenital hypothyroidism (CH, n=22). Sixty-four patients with AIT and 22 patients with CH were included in the analysis. The thyroid-stimulating hormone declined significantly from 25.8 ± 50.1 to 2.1 ± 1.5 μIU/mL (AIT group; p<0.01) and from 338.7 ± 380.7 to 1.9 ± 1.6 μIU/mL (CH group; p<0.01). The required T4 dose for patients with AIT was 1.5 ± 0.5 μg/kg per day (≥ 6 to <10 years: 2.0 ± 0.4 μg T4/kg per day; ≥ 10 to <12 years: 1.6 ± 0.4 μg T4/kg per day; ≥ 12 to <14 years: 1.5 ± 0.6 μg T4/kg per day; ≥ 14 years: 1.4 ± 0.6 μg T4/kg per day). It deviated significantly from the CH patients' mean T4 dose of 2.8 ± 0.7 μg T4/kg per day, p<0.01. CH patients with athyreosis required an average dose of 3.1 ± 0.5 μg T4/kg per day; patients with ectopia, 2.6 ± 0.7 μg T4/kg per day; and patients with dyshormonogenesis, 2.5 ± 0.6 μg T4/kg per day. Juvenile patients with AIT require significantly lower T4 doses than patients with CH.


  • Avoiding Harmful Procedures in Patients With Elevated α-Fetoprotein Concentrations

    by Walter Bonfig, Maja Hempel, Irene Teichert-Von Lüttichau, Susanne Liptay, Stefan Burdach

    Hereditary persistence of α-fetoprotein (AFP) is a rare but benign condition. A 13-year-old girl presented with dysmenorrhoic complaints and irregular cycles. Diagnostic workup revealed a cystic lesion of the ovary and elevated AFP; β-human chorionic gonadotrophin was negative. Right-sided ovarectomy was performed. Postsurgery AFP concentration did not decline. The patient underwent further diagnostic workup with negative results. Histology revealed follicular cysts but no tumor. Finally, hereditary persistence of AFP was suspected and AFP testing was performed in the family. It is important to include hereditary persistence of AFP in the differential diagnosis of elevated AFP concentrations to avoid harmful procedures.


  • Growth in Children and Adolescents with Type 1 Diabetes

    by Walter Bonfig, Thomas Kapellen, Axel Dost, Maria Fritsch, Tilman Rohrer, Johannes Wolf, Reinhard W. Holl


  • Overestimation of final height prediction in patients with classical congenital adrenal hyperplasia using the Bayley and Pinneau method

    by Walter Bonfig, Hans Peter Schwarz

    A typical growth pattern with decreased pubertal growth spurt has been identified in patients with classical congenital adrenal hyperplasia (CAH). To evaluate the accuracy of final height predictions in patients with CAH using the Bayley and Pinneau (B&P) method. Using growth and final height data of 92 patients (57 F/35 M) with CAH due to 21-hydroxylase deficiency (38 SV/54 SW), final height predictions with the B&P method were compared to actual final heights. In females, mean final height was 159.9 +/- 5.3 cm (-1.0 +/- 0.7 SDS) compared to predicted mean final height of 167.9 +/- 10.7 cm (+0.5 +/- 1.7 SDS), p < 0.001, overestimation 7.3 +/- 9.5 cm. In males, mean final height was 170.1 +/- 6 cm (-1.2 +/- 0.8 SDS) compared to predicted mean final height of 185.6 +/- 13.4 cm (+1.2 +/- 1.9 SDS), p < 0.001, overestimation 13.9 +/- 10.8 cm. In classical CAH, final height prediction using the B&P method results in significant overestimation of final height.


  • Recurrent hypoglycemia due to growth hormone deficiency in an infant with Turner syndrome

    by Walter Bonfig, Nabeel J.M. Salem, Katrin Heiliger, Maja Hempel, Gaby Lederer, Milena Bornkamm, Karen Wieland, Peter Lohse, Stefan Burdach, Konrad Oexle

    Growth hormone (GH) deficiency may occur in Turner syndrome (TS), but infantile hypoglycemia attributable to TS with GH deficiency has not been reported before. We report a puzzling case of neonatal hypoglycemia due to GH deficiency in Turner syndrome. Array CGH was used to scrutinize the complex TS karyotype. Standardized laboratory procedures. In a preterm (32 weeks) with prolonged and cholestatic jaundice, recurrent hypoglycemia occurred at the age of 1.5 months and was related to GH deficiency. There were no other endocrine or syndromic features. GH therapy was started at a usual dose of 25-30 μg/kg/day, but hypoglycemia recurred. Hepatopathy and hypogammaglobulinemia suggested X-recessive GH deficiency type 3 with non-random X-inactivation but resolved spontaneously. Nonetheless, a 45,X[75]/46,X,i(Xq)[21]/47,X,i(Xq)x2[4] TS karyotype was diagnosed with an apparent isochromosome fusion at the centromere. Upon this diagnosis, GH dose was doubled (50 μg/kg/day), and blood glucose was normalized consistently. In array CGH, the signal of Xp deviated more strongly than that of Xq, but the relation of the signals differed substantially from what the karyotype predicted. The isochromosome fusion point was relocated to Xp11.22, distal to a block of mental retardation genes that escape X-inactivation. i) TS with GH deficiency should be considered as a potential differential diagnosis of hypoglycemia in infants requiring higher doses of GH. ii) While array CGH may be erroneous in quantification of TS mosaicism, it is useful in precisely delineating isochromosomes and identifying genes on them that escape X-inactivation and thus possibly affect the TS phenotype.


  • Open Access

    GCK-MODY (MODY 2) Caused by a Novel p.Phe330Ser Mutation

    by Walter Bonfig, Sandra Hermanns, Katharina Warncke, Gabriele Eder, Ilse Engelsberger, Stefan Burdach, Annette Gabriele Ziegler, Peter Lohse

    Maturity onset diabetes of the young (MODY) is a monogenic form of diabetes inherited as an autosomal dominant trait. The second most common cause is GCK-MODY due to heterozygous mutations in theGCKgene which impair the glucokinase function through different mechanisms such as enzymatic activity, protein stability, and increased interaction with its receptor. The enzyme normally acts as a glucose sensor in the pancreatic beta cell and regulates insulin secretion. We report here a three-generation nonobese family diagnosed with diabetes. All affected family members presented with mild hyperglycemia and mostly slightly elevated hemoglobin A1c values. Genetic testing revealed a novel heterozygous T → C exchange in exon 8 of theGCKgene which resulted in a phenylalanine330TTC → serine (TCC)/p.Phe330Ser/F330S substitution.